Victory Capital Management Inc. Has $29.14 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Victory Capital Management Inc. decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 17.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 255,040 shares of the company’s stock after selling 52,476 shares during the period. Victory Capital Management Inc.’s holdings in Vaxcyte were worth $29,143,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the last quarter. RA Capital Management L.P. raised its holdings in shares of Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after purchasing an additional 312,500 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of Vaxcyte by 20.4% in the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after purchasing an additional 700,414 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Vaxcyte by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after buying an additional 498,359 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of research analyst reports. Jefferies Financial Group raised their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners raised their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. BTIG Research raised their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Bank of America raised their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $147.50.

Insider Activity

In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now directly owns 12,723 shares in the company, valued at $1,369,885.41. The trade was a 28.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Grant Pickering sold 2,366 shares of Vaxcyte stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the sale, the chief executive officer now owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 117,464 shares of company stock worth $12,640,276. 3.10% of the stock is owned by company insiders.

Vaxcyte Stock Down 6.3 %

Shares of NASDAQ:PCVX opened at $86.83 on Monday. The firm has a market capitalization of $10.82 billion, a PE ratio of -18.88 and a beta of 1.01. Vaxcyte, Inc. has a twelve month low of $48.24 and a twelve month high of $121.06. The company has a 50-day moving average price of $110.67 and a two-hundred day moving average price of $88.83.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the prior year, the business earned ($0.91) earnings per share. Analysts anticipate that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.